胸部恶性肿瘤的新兴疗法——免疫疗法、靶向治疗和非小细胞肺癌中的 T 细胞疗法。
Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer.
机构信息
Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
出版信息
Surg Oncol Clin N Am. 2020 Oct;29(4):555-569. doi: 10.1016/j.soc.2020.06.009. Epub 2020 Jul 29.
Abstract
Immunotherapy, targeted therapy, and adoptive T-cell therapy have been revolutionary advancements in cancer research. Some of these therapies have become the standard of care for lung cancer and replaced older treatment algorithms; some continue to be studied in clinical trials. This article discusses the current state of novel treatment options for non-small cell lung cancer patients with metastatic and locoregional disease, with focus on immunotherapy, targeted therapy, and adoptive T-cell therapy.
摘要
免疫疗法、靶向治疗和过继性 T 细胞疗法是癌症研究领域的革命性进展。其中一些疗法已成为肺癌的标准治疗方法，取代了旧的治疗方案；一些仍在临床试验中进行研究。本文讨论了转移性和局部区域性疾病非小细胞肺癌患者的新型治疗选择的现状，重点关注免疫疗法、靶向治疗和过继性 T 细胞疗法。
相似文献
1
Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer.胸部恶性肿瘤的新兴疗法——免疫疗法、靶向治疗和非小细胞肺癌中的 T 细胞疗法。
Surg Oncol Clin N Am. 2020 Oct;29(4):555-569. doi: 10.1016/j.soc.2020.06.009. Epub 2020 Jul 29.
2
Combining Immunotherapy with Radiation Therapy in Non-Small Cell Lung Cancer.免疫治疗联合放疗治疗非小细胞肺癌。
Thorac Surg Clin. 2020 May;30(2):221-239. doi: 10.1016/j.thorsurg.2020.01.002. Epub 2020 Mar 2.
3
Combining Immunotherapy and Chemotherapy for Non-Small Cell Lung Cancer.免疫疗法与化疗联合治疗非小细胞肺癌。
Thorac Surg Clin. 2020 May;30(2):199-206. doi: 10.1016/j.thorsurg.2020.01.006. Epub 2020 Mar 2.
4
Efficacy of cascade-primed cell infusion as an adjuvant immunotherapy with concurrent chemotherapy for patients with non-small-cell lung cancer: A retrospective observational study with a 5-year follow-up.级联预刺激细胞输注联合化疗作为非小细胞肺癌辅助免疫治疗的疗效：一项 5 年随访的回顾性观察研究。
Cytotherapy. 2020 Jan;22(1):35-43. doi: 10.1016/j.jcyt.2019.12.002. Epub 2020 Jan 3.
5
Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer.肺癌的靶向治疗与免疫检查点治疗
Surg Pathol Clin. 2020 Mar;13(1):17-33. doi: 10.1016/j.path.2019.11.002.
6
Principles of Immunotherapy in Non-Small Cell Lung Cancer.非小细胞肺癌的免疫治疗原则。
Thorac Surg Clin. 2020 May;30(2):187-198. doi: 10.1016/j.thorsurg.2020.01.009.
7
Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.非小细胞肺癌治疗中的靶向治疗与免疫治疗
Radiol Clin North Am. 2018 May;56(3):485-495. doi: 10.1016/j.rcl.2018.01.012.
8
Evolving Treatment Options for Lung Cancer.肺癌不断发展的治疗选择
Hematol Oncol Clin North Am. 2017 Feb;31(1):xiii-xiv. doi: 10.1016/j.hoc.2016.09.001.
9
Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome.非小细胞肺癌的现行过继免疫疗法及其对治疗效果的潜在影响。
Cancer Invest. 2013 Mar;31(3):197-205. doi: 10.3109/07357907.2013.775294.
10
Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.用于治疗非小细胞肺癌的主动特异性免疫疗法和细胞转移疗法。
Lung Cancer. 2009 Jul;65(1):1-8. doi: 10.1016/j.lungcan.2008.10.018. Epub 2008 Dec 4.
引用本文的文献
1
Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues.非小细胞肺癌新辅助免疫治疗的文献计量学洞察：趋势、合作及未来方向
Front Immunol. 2025 Feb 10;16:1533651. doi: 10.3389/fimmu.2025.1533651. eCollection 2025.
2
Progress and application of lung-on-a-chip for lung cancer.肺癌芯片肺模型的研究进展与应用
Front Bioeng Biotechnol. 2024 May 24;12:1378299. doi: 10.3389/fbioe.2024.1378299. eCollection 2024.
3
Progress in the treatment of lung adenocarcinoma by integrated traditional Chinese and Western medicine.中西医结合治疗肺腺癌的研究进展
Front Med (Lausanne). 2024 Jan 8;10:1323344. doi: 10.3389/fmed.2023.1323344. eCollection 2023.
4
High expression of PD-L1 mainly occurs in non-small cell lung cancer patients with squamous cell carcinoma or poor differentiation.PD-L1 高表达主要发生于非小细胞肺癌患者中的鳞癌或低分化癌患者中。
Oncol Res. 2023 May 24;31(3):275-286. doi: 10.32604/or.2023.028227. eCollection 2023.
5
T lymphocyte cell: A pivotal player in lung cancer.T 淋巴细胞：肺癌的关键参与者。
Front Immunol. 2023 Jan 27;14:1102778. doi: 10.3389/fimmu.2023.1102778. eCollection 2023.
6
Prognostic Value of Immunotyping Combined with Targeted Therapy in Patients with Non-Small-Cell Lung Cancer and Establishment of Nomogram Model.免疫分型联合靶向治疗对非小细胞肺癌患者的预后价值及列线图模型的建立。
Comput Math Methods Med. 2022 May 14;2022:3049619. doi: 10.1155/2022/3049619. eCollection 2022.
7
A targeted siRNA-loaded PDL1-exosome and functional evaluation against lung cancer.载有靶向 siRNA 的 PD-L1 外泌体及其对肺癌的功能评估。
Thorac Cancer. 2022 Jun;13(11):1691-1702. doi: 10.1111/1759-7714.14445. Epub 2022 May 11.
8
POU2F2 promotes the proliferation and motility of lung cancer cells by activating AGO1.POU2F2 通过激活 AGO1 促进肺癌细胞的增殖和迁移。
BMC Pulm Med. 2021 Apr 8;21(1):117. doi: 10.1186/s12890-021-01476-9.
本文引用的文献
1
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC.新辅助 PD-1 抑制剂（信迪利单抗）治疗 NSCLC。
J Thorac Oncol. 2020 May;15(5):816-826. doi: 10.1016/j.jtho.2020.01.017. Epub 2020 Feb 6.
2
Directing Traffic: How to Effectively Drive T Cells into Tumors.引导交通：如何有效地将 T 细胞引导至肿瘤中。
Cancer Discov. 2020 Feb;10(2):185-197. doi: 10.1158/2159-8290.CD-19-0790. Epub 2020 Jan 23.
3
Targeting cancers through TCR-peptide/MHC interactions.通过 TCR-肽/MHC 相互作用靶向癌症。
J Hematol Oncol. 2019 Dec 18;12(1):139. doi: 10.1186/s13045-019-0812-8.
4
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with mutations.阿替利珠单抗联合贝伐珠单抗、紫杉醇和卡铂用于转移性非鳞状非小细胞肺癌患者的一线治疗，包括 突变患者。
Expert Rev Respir Med. 2020 Feb;14(2):125-136. doi: 10.1080/17476348.2020.1701439. Epub 2019 Dec 12.
5
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
6
Engineered T Cell Therapy for Cancer in the Clinic.临床肿瘤的工程化 T 细胞疗法。
Front Immunol. 2019 Oct 11;10:2250. doi: 10.3389/fimmu.2019.02250. eCollection 2019.
7
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.洛拉替尼治疗晚期 ROS1 阳性非小细胞肺癌：多中心、开放标签、单臂、1 期-2 期试验。
Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25.
8
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.采用 NY-ESO-1 SPEAR T 细胞过继转移后滑膜肉瘤的全身和局部免疫。
J Immunother Cancer. 2019 Oct 24;7(1):276. doi: 10.1186/s40425-019-0762-2.
9
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
10
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
Zotero 插件